Cargando…

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoro, Marco, Mancuso, Salvatrice, Accurso, Vincenzo, Di Lisi, Daniela, Novo, Giuseppina, Siragusa, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287514/ https://www.ncbi.nlm.nih.gov/pubmed/34290617 http://dx.doi.org/10.3389/fphys.2021.675811

Ejemplares similares

The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
por: Mancuso, Salvatrice, et al.
Publicado: (2020)

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate
por: Napolitano, Mariasanta, et al.
Publicado: (2017)

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
por: Accurso, Vincenzo, et al.
Publicado: (2019)

Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia
por: Santoro, Marco, et al.
Publicado: (2022)

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity
por: Di Lisi, Daniela, et al.
Publicado: (2022)

Familial essential thrombocythemia: 6 cases from a mono‐institutional series
por: Accurso, Vincenzo, et al.
Publicado: (2022)

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival
por: Accurso, Vincenzo, et al.
Publicado: (2020)

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep
por: Accurso, Vincenzo, et al.
Publicado: (2020)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
por: Aghel, Nazanin, et al.
Publicado: (2017)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
por: Stuckey, Ruth, et al.
Publicado: (2023)

Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy
por: Mancuso, Salvatrice, et al.
Publicado: (2022)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
por: Caocci, Giovanni, et al.
Publicado: (2020)

Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy
por: Nodzon, Lisa, et al.
Publicado: (2022)

Immunosenescence and lymphomagenesis
por: Mancuso, Salvatrice, et al.
Publicado: (2018)

Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma
por: Mancuso, Salvatrice, et al.
Publicado: (2022)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
por: Wieczorek, Agnieszka, et al.
Publicado: (2016)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia
por: Prashar, Abhisheik, et al.
Publicado: (2020)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022)

Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands
por: Zhao, Meng, et al.
Publicado: (2020)

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
por: Boquimpani, Carla, et al.
Publicado: (2022)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j816rtef6pvsb9rqur592rjha1